OA18256A - Anthostema senegalense-based composition, for use as an anti-AIDS drug. - Google Patents
Anthostema senegalense-based composition, for use as an anti-AIDS drug. Download PDFInfo
- Publication number
- OA18256A OA18256A OA1201700123 OA18256A OA 18256 A OA18256 A OA 18256A OA 1201700123 OA1201700123 OA 1201700123 OA 18256 A OA18256 A OA 18256A
- Authority
- OA
- OAPI
- Prior art keywords
- anthostema senegalense
- composition based
- pharmaceutical composition
- senegalense
- anthostema
- Prior art date
Links
- 241001553164 Anthostema senegalense Species 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 229940079593 drugs Drugs 0.000 title claims abstract description 12
- 239000000419 plant extract Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims abstract description 15
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 7
- 239000004005 microsphere Substances 0.000 claims abstract description 7
- 238000001125 extrusion Methods 0.000 claims abstract description 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 22
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 229930003231 vitamins Natural products 0.000 claims description 6
- 229940029983 VITAMINS Drugs 0.000 claims description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 5
- 229960002555 Zidovudine Drugs 0.000 claims description 5
- 238000005563 spheronization Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940098465 Tincture Drugs 0.000 claims description 4
- 230000000840 anti-viral Effects 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 230000001476 alcoholic Effects 0.000 claims description 3
- -1 ampoules Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000004676 glycans Polymers 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229960002477 Riboflavin Drugs 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229940011671 Vitamin B6 Drugs 0.000 claims description 2
- 229930003629 Vitamin B6 Natural products 0.000 claims description 2
- 235000019568 aromas Nutrition 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 230000001050 lubricating Effects 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019160 vitamin B3 Nutrition 0.000 claims description 2
- 239000011708 vitamin B3 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 claims description 2
- 240000006245 Dichrostachys cinerea Species 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 208000005721 HIV Infections Diseases 0.000 abstract description 6
- 230000000798 anti-retroviral Effects 0.000 abstract 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 6
- 229960002656 didanosine Drugs 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 5
- 229960000689 Nevirapine Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005325 percolation Methods 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 239000006286 aqueous extract Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 231100000486 side effect Toxicity 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000004366 CD4-Positive T-Lymphocytes Anatomy 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 229920000126 Latex Polymers 0.000 description 3
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical class CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 229940095731 Candida albicans Drugs 0.000 description 2
- 206010007134 Candida infection Diseases 0.000 description 2
- 241000006479 Cyme Species 0.000 description 2
- 240000003241 Silphium laciniatum Species 0.000 description 2
- 235000009543 Silphium laciniatum Nutrition 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 244000020998 Acacia farnesiana Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N Sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 231100000185 significant adverse effect Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to a pharmaceutical composition based on Anthostema senegalense used as a drug in the treatment of HIV infection, AIDS and accompanying clinical manifestations. The composition can be used as an antiretroviral drug against HIV type 1 or HIV type 2. The composition preferably comprises a polar and/or apolar plant extract of Anthostema senegalense, preferably obtained from the stem bark of Anthostema senegalense. The composition is preferably formulated in the form of microspheres produced using an extrusion and spheronisation” method, and then grouped together in capsules.
Description
LABORATOIRE MICHEL IDERNE and
BALDE Aliou Mamadou
COMPOSITION BASED ON ANTHOSTEMA SENEGALENSE, FOR USE AS AN ΑΝΤΙ-AIDS DRUG
The présent invention relates to the use of Anthostema-senegalense in the préparation of a drug for the treatment of the infection with the Human Immunodeficiency Virus (HIV), of AIDS (Acquired Immunodeficiency Syndrome) and the accompanying clinical manifestations.
The acquired immunodeficiency syndrome, better known by its acronym AIDS, is a disease that results in a sériés of symptoms following the destruction of cells of the immune system by a retrovirus referred to as human immunodeficiency virus or HIV, two types are currently known: HIV-l and HIV-2. AIDS is the last stage of the infection with this virus, which generally leads to the death of the people infected with op portunistic diseases.
The transmission of the AIDS virus occurs through sexual, blood, or mother-tochild transmission (through the placenta or during childbirth and/or breastfeeding). The viral particles of HIV présent in the body fluids infect the cells of the immune system, in particular the T4 lymphocytes, which possess suitable receptors (the CD4 proteins).
As a resuit of the primary infection, the patient goes through an asymptomatic phase that can last for about ten years, during which he exhibits no symptoms of the disease, but during which his T4 lymphocytes and his macrophages are progressively destroyed by the HIV. At this stage, the individual has antibodies directed against the virus: he is said to be HIV-positive.
When his immune system is too weak, the symptoms of AIDS appear. Opportunistic diseases break out, such as for example tuberculosis, pneumonia or pneumocystis, but also herpes, or cancers (Kaposi's sarcoma, lymphomas, etc.), which can lead to the death of the patient.
The infection with the HIV virus is an épidémie that developed from the late
1970s and is now affecting the entire planet, both the developed countries and the developing countries, making this disease a global health problem. According to an estimate by the World Health Organization (WHO) dated December, 2012, more than million people would be infected with the HIV virus worldwide, among whom 3.3 million children under 15 years of âge. Sub-Saharan Africa alone would account for
69% of the cases. There would be approximately 2.5 million new infections annually, and 1.7 million deaths were reported in 2011.
Currently, it is not possible to cure AIDS and prévention, especially the use of a condom, remains the best option to fight the HIV viras, because there is currently no vaccine permitting to be protected against this viras.
There are nevertheless treatments that permit to slow down the évolution of the disease towards the AIDS stage. These treatments consist in taking one or preferably several antiviral molécules in combination for a higher efficiency. The triple thérapies, which group three antiviral molécules, are generally recommended and are considered as being the most effective to contain the action of the viras and to stop its prolifération within the organism.
These treatments, which must be continued throughout the patients' lives, are very expensive and are therefore only very rarely available in the developing countries because the populations cannot bear the financial burden. In these countries, namely in Africa and in Asia, where the viras is very présent, a vast majority of patients do nowadays not benefit from any effective treatment. Now, in the absence of a treatment, almost ail HIV-infected patients progress to AIDS, and then to death.
In addition, even in countries where the triple thérapies are prescribed, the latter are not effective on ail patients. Indeed, there is a significant proportion of patients treated for whom this type of treatment remains ineffective (virological escape), even completely ineffective (therapeutic failure).
Furthermore, even when they are effective, these treatments hâve significant adverse effects as well as some toxicity, which reduces the patients' quality of life. Some patients, who no longer withstand these side effects, stop their treatment, whereas the latter must be followed very consistently in order to avoid making the virus résistant.
Finally, the molécules used in the triple thérapies are often fragile molécules that require strict conditions of préservation, which is particularly problematic in hot and/or humid countries, namely in Africa and Asia.
In the developing countries, namely in Africa, it would be particularly interesting for ail these reasons to hâve an effective and much cheap er treatment, obtained from local plants and in a form that does not raise préservation problems.
This is the aim of the invention, the aim of which is to provide an effective drug, which generates fewer side effects and the cost of which remains low compared to the cost of the triple thérapies currently recommended in case of infection with the HIV.
This drug could also be provided in the developed countries as a complément to the current triple thérapies for better effïciency or for treating undesirable side effects, or to replace them for économie reasons, to limit the side effects or in the cases where the conventional treatments are ineffective.
In order to solve this technical problem, the invention teaches a pharmaceutical composition based on Anthostema senegalense for its use as a drug in the treatment of the infection with the Human Immunodeficiency Virus (HIV), of AIDS and the accompanying clinical manifestations.
This pharmaceutical composition can be used as an antirétroviral drug against the HIV virus of the type 1 or the type 2.
Advantageously, the composition according to the invention has little or no side effects and is much cheaper than conventional drugs against AIDS. It is thus much better accepted by the patients for a regular long tenu treatment.
Moreover, its effect is enhanced by the other components présent in the plant, which are mixed with the active ingrédient when the therapeutic composition is produced. The totum thus has an improved effect with respect to the active ingrédient in the isolated state.
In addition and as frequently occurs with natural extracts of not chemically modified plants, the active ingrédient of the pharmaceutical composition of the invention has very few risks of overdosing.
Further features and advantages of the invention will become clear from reading the following detailed description.
Anthostema senegalense is a flowering plant of the Euphorbiaceae family.
This is a forest free that can reach 30 m in height, with altemate, glabrous, simple, coriaceous leaves that are cuneifonn at the base, with gutter-shaped petiole and deciduous leaf-like formation, elliptic-lanceolate tough foliage reaching up to 15 cm in length and 5-6 cm in width, cuneate at the base, acuminate at the top, penni-veins, 1020 pairs of latéral veins. Its latex is white and its flowers are cyathiums grouped into small, from shortly pedunculate to subsessile axillary cymes. It has inflorescences in cyme, carrying at each branch an involucre of bracts enveloping numerous male flowers and one female flower. Its fruits are deeply tri-lobed capsules, containing three gray-yellowish-gray ovoid seeds spotted with brown of about 15 mm in length and 205 25 mm in width.
Anthostema senegalense grows in the forest fringes along the rivers.
The species is endemic in West Africa where it can be found in the forest galleries in Guinea, Mali, Ivory Coast, Liberia, Sénégal, Burkina Faso, Gambia, Guinea-Bissau, Sierra Leone, Bénin and Nigeria. This plant is uncommon and in danger of extinction 10 in some countries such as Ivory Coast due to the disturbance of its natural site.
For the préparation of the pharmaceutical composition according to the invention, the stem bark of Anthostema senegalense is preferably used, preferably after having been dried to remove the latex from same.
Although less advantageous, other parts of the Anthostema senegalense plant 15 could also or alternatively be used to préparé the composition used according to the invention, such as for example its leaves, or its latex, although more toxic.
The pharmaceutical composition used according to the invention preferably comprises a plant extract of Anthostema senegalense. This plant extract is preferably a vegetable solution or a liquid plant extract and for example, according to its 20 concentration, a mother tincture, a tincture officinalis or a liquid extract of Anthostema senegalense.
This plant extract of Anthostema senegalense is a polar extract, for example an aqueous, alcoholic or hydro-alcoholic; or apolar extract.
This plant extract is obtained by any suitable means and namely by extraction, 25 preferably aqueous, alcoholic or hydro-alcoholic extraction, by macération, infusion, décoction, percolation, digestion, leaching or the like.
A polar plant extract may for example be obtained by an extraction with methanol or éthanol.
An apolar plant extract may for example be obtained by extraction with 30 dichloromethane (CFBCl?), chlorofonn (CHCI3) or with ethyl acetate (CH3COOC2H5).
Another polar plant extract may for example be obtained by percolation with methanol through the marc resulting from the extraction with dichloromethane.
According to a preferred embodiment of the invention, a liquid plant extract is prepared from stem bark of Anthostema senegalense by means of a hydro-alcoholic extraction by a percolation technique with stirring. Its alcohol content is preferably between 30 and 70°.
By way of an example, an Anthostema senegalense mother tincture was prepared with an éthanol content of about 70% V/V from dry bark of Anthostema senegalense by exhaustive cold percolation followed by concentration under vacuum with the rotary evaporator.
The composition used according to the invention can adopt different galenic, preferably oral, fonns. It can thus be for example in the form of infusettes containing for example about 5 grams of stem bark of roughly ground Anthostema senegalense.
It can also be in the form of tablets, preferably orodispersible tablets, of soft capsules, of granules, capsules, powder, ampoules, syrup, decoctate, fluid extract or any other suitable galenic form, preferably oral form, imaginable by those skilled in the art.
Preferably, the composition intended to be used according to the invention is formulated in the form of microspheres, also referred to as spheroids, preferably grouped into capsules in an amount corresponding preferably to a unit dose, for example a daily dose.
Thus, the benefits are the numerous advantages of this galenic form, namely in the medical field a quick release and a high bioavailability of the active ingrédients and at practical level a great ease of use for the patient and a very little fragile and very stable form at long term, even under difficult storage conditions.
These microspheres can be made by various methods.
A first method consists for example in preparing a peripheral layer containing the plant extract of Anthostema senegalense around a neutral core, formed for example of a mixture of sugar and starch or of a sugar crystal, of mannitol or sorbitol.
The layer containing the plant extract of Anthostema senegalense can advantageously be prepared by coating, imprégnation, spraying or projection, the active ingrédient being to this end preferably mixed with a mounting agent or a binder.
According to a second preferred method, the microspheres or spheroids can be fonned by extrusion and spheronization.
To this end, the plant extract of Anthostema senegalense is first mixed with an absorbing and adsorbent substance, preferably such as a natural or synthetic polymer, having plastic properties compatible with the extrusion and spheronization steps of the subséquent part of the method.
These are for example microcrystalline cellulose, micro-fine cellulose, a substituted weakly hydroxypropylated cellulose polymer, starch, modified starch, polysaccharides or any other suitable substance or mixture.
If the mixture is too dry, an aqueous or non-aqueous humidification liquid may also be added in order to obtain a homogeneous and malléable paste capable of undergoing the following steps of the method.
The humidifying liquid also serves as a vehicle for carrying and depositing the active ingrédient until the core of the absorbing and adsorbent material in the microcavities of the polymer.
The manufacturing method then consists in extruding the wet mass through a die with calibrated orifices. In this way, compact filaments having a generally cylindrical and defined cross-section, referred to as extradâtes, are obtained.
These extradâtes are then placed in a cylindrical apparatus referred to as spheronizer containing in the lower portion a key-shaped dise rotating at a varying and controlled speed. Under the effect of the centrifugal force exerted by the rotation of the rotating dise, the extradâtes fragment regularly, then turn into spheres by a rolling-binding effect. The desired spheroids are thus obtained.
These two methods may also comprise at least a drying step and/or a calibrating step.
The drying can occur by slightly heating, for example at a température between 30 and 40°C or by a simple exposure to the open air for a suffi ci ent period of time.
Finally, the resulting spheroids may optionally be coated on the periphery with an outer film in order to protect them, for example from external moisture, heat, aggressive conditions of the body or a delayed effect.
Besides the plant extract of Anthostema senegalense, the composition intended for use according to the invention may in addition comprise one or several othei’ suitable compounds or excipients, for example chosen from extracts from one or several other plants, vitamins, minerais, trace éléments, aromas, mounting agents, binding compounds, sliding compounds, lubricating compounds, surfactants, sugars, lactose, sorbitol, mannitol, starches or modified starches, maltodextrins, carbonates, citrates, gelatin, polyvinylpyrrolidone, polysaccharides, cellulose dérivatives, crosslinked sodium carboxymethylcellulose, microcrystalline cellulose, micro-fine cellulose, weakly substituted hydroxypropylated cellulosic polymers or any other suitable compound.
It may also comprise one or several compounds increasing the effectiveness of Anthostema senegalense, protecting it or helping its quick release.
It may also comprise, in combination, one or several other known antiviral or antirétroviral substances, namely one or several of those used within the framework of the conventional treatments against AIDS (triple thérapies or the like). The composition according to the invention may thus comprise for example, besides Anthostema senegalense, zidovudine or azidothymidine (AZT), in order to reinforce its anti-HIV activity.
The following examples will permit to better illustrate the invention:
Example 1 :
Spheroids were prepared by the extrusion and spheronization method described above, starting from an hydro-alcoholic extract of stem bark of Anthostema senegalense, prepared according to the European pharmacopoeia, with an éthanol content of 70% V/V and a dry residue of about 10%. These spheroids were grouped into 350 mg capsules.
For a 350 mg capsule:
• Extract from Anthostema senegalense 350 ml dry residue équivalent 35 mg • micro-cellulose q.s.
The spheroids obtained were grouped into 350 mg capsules corresponding to a unit dose of composition, for a preferred dosage of three capsules per day.
Example 2:
Since taking vitamins and minerais is bénéficiai for improving the general health of immunosuppressed people, spheroids containing a mixture of vitamins and sélénium in addition to the plant extract hâve been prepared.
These spheroids were prepared as above from the described hydro-alcoholic extract of stem bark of Anthostema senegalense.
Before extrusion and spheronization, vitamins and sélénium were however added to this extract in the following proportions:
| For 2.1 kg of extract: | |
| • vitamin PP: | 70 g |
| • vitamin Bl: | 8g |
| • vitamin B2: | 8g |
| • vitamin B6: | 8g |
| • sélénium: | 48g |
The spheroids obtained were grouped into 350 mg capsules.
In order to demonstrate the anti-HIV properties of the composition intended to be used according to the invention, the présent inventors conducted two studies: a sériés of in vitro tests and a clinical test, which permitted to conclude that a composition based on Anthostema senegalense was efficient. The results of these studies are summarized below.
In vitro tests:
An apolar extract and a polar extract of Anthostema senegalense were prepared by extraction with dichloromethane and methanol, respectively, fforn dried stem bark of Anthostema senegalense.
The efficacy of these extracts against the HIV virus was tested in vitro by measuring the médian inhibitory concentration (IC50) of these substances on the type 1
HIV virus (strain IIIr) and on the type 2 virus (strain ROD). Their selectivity index was also measured in each case.
In order to serve as a control, three known antirétroviral molécules used in the treatment of the infection with HIV: nevirapine, dideoxycitidine and dideoxyinosine were also tested under the same conditions for comparison.
The results obtained are summarized in the table below:
| HIV-1 Strain ΙΙΙβ | HIV-2 ROD Strain | |||
| Sample tested | IC50 (pg/ml) | Index of selectivity | ic50 (pg/ml) | Index of selectivity |
| Anthostema senegalense apolar extract (CH2CI2) | 0.250 | 119 | 0.0519 | 714 |
| Anthostema senegalense polar extract (MeOH) | 2.04 | 24 | 0.42 | 132 |
| Nevirapine | 0.047 | >4.00 | ||
| Dideoxycitidine | 0.29 | 0.30 | ||
| Dideoxyinosine | 2.89 | 4.59 |
It was found that the polar and apolar extracts of Anthostema senegalense exert in vitro a significant inhibition of each of both types of HIV (HIV-1 and HIV-2) tested 5 with a satisfactory selectivity index.
The apolar extract has a very pronounced inhibitory activity against HIV-1, comparable to that of dideoxycitidine and better than that of dideoxyinosine. This activity is even better against HIV-2 for which it is significantly better than that of nevirapine, dideoxycitidine and dideoxyinosine.
The polar extract has a pronounced inhibitory activity against HIV-1, somewhat less good than that of nevirapine and dideoxycitidine, but slightly better than that of dideoxyinosine, and very pronounced against HIV-2 for which it is comparable to that of dideoxycitidine and significantly better than that of nevirapine and dideoxyinosine.
Clinical test :
Six naïve HIV-positive patients, i.e. who never took an antirétroviral treatment against HIV, were treated for several months with an aqueous extract of
Anthostenia senegalense (patient 5) or a hydro-alcoholic extract of Anthostema senegalense (patients 2, 3 and 4) or also with infusettes containing dried stem bark of
Anthostema senegalense (patients 1 and 6).
The aqueous extract was prepared by décoction for 15 minutes of 500 g dried and crushed bark of Anthostema senegalense in 1 liter of water, followed by filtration. A half water glass (about 10 cl) of this décoction was given daily to the patients treated with the aqueous extract.
The hydro-alcoholic extract was prepared at room température by percolation of kg dried and ground bark of Anthostemci senegalense, then by concentration of the extract obtained until one liter of fluid hydro-alcoholic extract was obtained. One teaspoon (i.e. about 5 ml) of this fluid extract was given daily to the patients treated with the hydro-alcoholic extract.
For the infusettes, 5 g dried and crushed bark of Anthostema senegalense were placed in each infusette. The patients treated with infusettes took one of them each day.
The CD4 cell count of these patients, corresponding to the number of CD4 cells per mm of blood and reflecting the patient's T4 lymphocytes count, was measured monthly throughout the study.
The results obtained are summarized in the following table:
| CD4 count | |||||||
| Patient 1 F, 32 years infusettes | Patient 2 F, 23 years hydroalcoholic extract | Patient 3 M, 46 years hydroalcoholic extract | Patient 4 F, 24 years hydroalcoholic extract | Patient 5 M, 48 years aqueous extract | Patient 6 F, 30 years infusettes | Average ±SD | |
| Month 1 | 134 | 118 | 276 | 142 | 218 | 110 | 166 ±66 |
| Month 2 | 186 | 120 | 290 | 178 | 200 | 124 | 183 ±62 |
| Month 3 | 180 | 140 | 325 | 132 | 264 | 116 | 192 ±84 |
| Month 4 | 128 | 205 | 380 | 180 | 280 | 102 | 213 ±103 |
| Month 5 | 150 | 280 | 215 | 215 ±65 | |||
| Month 6 | 162 | 200 | 230 | 197 ±34 | |||
| Month 7 | 180 | 290 | 235 ±78 |
It was found that the treatment with the composition used according to the invention permitted to improve the CD4 cell count in five out of six patients after four to seven months of follow-up. Their CD4/CD8 cell ratio has also been improved.
In addition, an improvement and even disappearance of some clinical manifestations of the infection by the HIV hâve been noticed in these patients:
The composition according to the invention thus permitted to treat:
- chronic diarrhea in three patients;
- dermatoses in two patients;
- dennal allergies in four patients.
The disappearance of these clinical manifestations of the infection with the HIV, by taking the composition used according to the invention, has permitted to considerably improve the quality of life of these patients.
Thus, in addition to a réduction of the infection with the HIV virus resulting into an increase in the CD4 cell count, an improvement in the overall health of the patients related to the disappearance of clinical manifestations related to the infection with the HIV virus is also observed.
The présent inventors hâve also noticed that the composition based on Anthostema senegalense used according to the invention also has antifungal properties, namely against Candida albicans, a fungus responsible for candidiasis, which is a disease frequently found in patients infected with the HIV virus.
In vitro biological studies hâve thus permitted to show that the polar methanol extract from the stem bark of Anthostema senegalense has a significant activity with respect to Candida albicans with a médian inhibitory concentration (IC50) equal to 29.71 pg/ml, thus conferring to the composition according to the invention a therapeutic potential of interest for the treatment of candidiasis.
It is once again observed that the composition based on Anthostema senegalense used according to the invention also in addition advantageously permits to treat the clinical manifestations related to the infection with the HIV virus.
This composition offers an effective and much cheaper alternative to the current triple thérapies for the treatment of the infection with the HIV virus, of AIDS and the accompanying clinical manifestations.
As set forth above, it can in addition be provided in a galenic form, which does not raise any préservation problems.
For ail these reasons, the composition used according to the invention seems to be an extremely promising therapeutic solution for the developing countries.
Obviously, the invention is not restricted to the preferred embodiments described above, since those skilled in the art can bring numerous modifications and imagine other variants without departing front the scope nor from the ffamework of the invention defined by the claims.
Claims (15)
1. A pharmaceutical composition based on Anthostema senegalense for its use as a drug in the treatment of the infection with the Human Immunodeficiency Virus
2. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 1 as an antirétroviral drug for type 1 or type 2 HIV virus.
3. The pharmaceutical composition based on Anthostema senegalense foi’ its use according to any one of the preceding claims, wherein it is obtained from stem bark of
4. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 3, wherein it is obtained from dried stem bark.
5 vitamin PP, vitamin B1, vitamin B2, vitamin B6 or sélénium.
5. The pharmaceutical composition based on Anthostema senegalense for its use according to any one of the preceding claims, wherein it comprises a plant extract of
15 Anthostema senegalense.
5 (HIV), AIDS and the accompanying clinical manifestations.
6. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 5, wherein the plant extract of Anthostema senegalense is a polar, aqueous, alcoholic or hydro-alcoholic extract.
7. The pharmaceutical composition based on Anthostema senegalense for its use
20 according to claim 6, wherein the plant extract of Anthostema senegalense is a mother tincture of Anthostema senegalense with an éthanol content of about 70% V/V.
8. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 5, wherein the plant extract of Anthostema senegalense is an apolar extract.
25
9. The pharmaceutical composition based on Anthostema senegalense for its use according to any one of the preceding claims, wherein it comprises in addition one or several compounds or excipients chosen from extracts from plant extracts, vitamins, minerais, trace éléments, aromas, mounting agents, binding compounds, sliding compounds, lubricating compounds, surfactants, sugars, lactose, sorbitol, mannitol,
30 starches and modified starches, maltodextrins, carbonates, citrates, gelatin, polyvinylpyrrolidone, polysaccharides, cellulose dérivatives, crosslinked sodium carboxymethylcellulose, microcrystalline cellulose, micro-fine cellulose, weakly substituted hydroxypropylated cellulosic polymers, and the antiviral or antirétroviral substances.
10 tablets, orodispersible tablets, soft capsules, granules, capsules, powder, ampoules, syrup, décoction or fluid extract.
10. The pharmaceutical composition based on Anthostema senegalense foi' its use according to claim 9, wherein it comprises in addition zidovudine, azidothymidine,
10 Anthostema senegalense.
11. The pharmaceutical composition based on Anthostema senegalense for its use according to any one ofthe preceding claims, wherein it is in an oral galenic fonn.
12. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 11, wherein it is in a galenic fonn of infusettes, microspheres,
13. The pharmaceutical composition based on Anthostema senegalense for its use according to claim 12, wherein it is in a galenic fonn of infusettes containing about five grams of coarsely crushed stem bark of Anthostema senegalense.
15
14. The phannaceutical composition based on Anthostema senegalense for its use according to claim 12, wherein it is in a galenic form of microspheres produced by an extrusion and spheronization method.
15. The phannaceutical composition based on Anthostema senegalense for its use according to claim 14, wherein the microspheres are grouped into capsules.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1455226 | 2014-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA18256A true OA18256A (en) | 2018-09-17 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dinda et al. | The genus Sida L.–A traditional medicine: Its ethnopharmacological, phytochemical and pharmacological data for commercial exploitation in herbal drugs industry | |
| Meher et al. | Pharmacological profile of Terminalia chebula Retz. and Willd.(Haritaki) in Ayurveda with evidences | |
| CN102178753B (en) | Medicinal preparation with effects of clearing heat, purging intense heat, detoxifying, eliminating blood stasis, cooling blood and stopping bleeding | |
| Rahaman et al. | Assessment of thrombolytic, antioxidant and analgesic properties of a medicinal plant of Asteraceae family growing in Bangladesh | |
| Dharani et al. | An Illustrated Guide to Medicinal Plants of East Africa | |
| Guna | Theraprutic value of arctium lappa linn-a review | |
| UA99773C2 (en) | Lozenge composition for treating inflammatory diseases of the mouth and pharynx | |
| US10517826B2 (en) | Anthostema senegalense-based composition for use as an anti-AIDS drug | |
| JP7029886B2 (en) | Pharmaceutical composition and its manufacturing method | |
| OA18256A (en) | Anthostema senegalense-based composition, for use as an anti-AIDS drug. | |
| BOOPATHI | Medicinal & Poisonous Plants of India | |
| KR101083873B1 (en) | Elimination process of the ingredient inhibiting blood coagulation in Artemisia | |
| JP2011079817A (en) | Compositions for preventing and/or treating viral infectious diseases, comprising plant extract, agent for preventing and/or treating viral infectious disease, having them as active ingredients, and inhibitor for adsorption onto viral cell | |
| Omodale et al. | Protective effect of aqueous root extract of Gongronema latifolium against paracetamol induced hepatotoxicity and chloroquine induced nephrotoxicity in rats | |
| CN100443073C (en) | Chinese Apea Ear-ring preparation capable of improving drug effect and preparation method thereof | |
| US8703213B2 (en) | Anti-diabetic composition containing a plant extract of Englerina lecardii | |
| JPS60260520A (en) | Drug composition | |
| KR102030123B1 (en) | Composition for preventing or treating hearing loss | |
| Jalwal et al. | Optimization formulation and evaluation of Senna tablets for the treatment of constipation | |
| Ramchander et al. | Optimization formulation and evaluation of senna tablets for the treatment of constipation | |
| Kagalkar et al. | Development & evaluation of herbal fast dissolving tablet of Bauhenia veriagata Linn | |
| RU2331430C1 (en) | Medicinal herbal mix for stomach ulcer prevention and complex treatment | |
| Williamson | Use of Geranium species extracts as herbal medicines | |
| Enemor et al. | Sub-acute effects of orally administered Ethanol extract of Root of Sarcocephalus latifolius (African peach) on Liver function markers of Wistar albino Rats | |
| Kagalkar et al. | Development & evaluation of herbal fast dissolving tablet of Tectona grandis Linn & Bauhenia veriagata Linn. mixture |